Average Weight Loss on Wegovy: What the Evidence Really Shows

The myth: everyone loses 15% (why that number needs context

The 15% headline comes from STEP 1, published in the New England Journal of Medicine) a rigorous, randomised trial of 1,961 adults with obesity or overweight and at least one weight-related condition, none of whom had type 2 diabetes. After 68 weeks on 2.4mg weekly semaglutide alongside lifestyle support, the average reduction in body weight was 14.9%, compared with 2.4% on placebo. That is a genuine, large-scale result. But an average hides a distribution. Roughly one third of participants lost more than 20% of their body weight; a smaller group lost under 5%. Age, starting weight, how consistently doses were taken, the quality of accompanying lifestyle changes and individual metabolic factors all shift where someone lands on that curve.

The most useful thing a reader can do in under a minute is to note their current weight, then mentally mark 10%, 15% and 20% of it. Those three numbers frame the realistic range for most people, not a promise, but a reference point grounded in real trial data. If you want a fuller breakdown of what the numbers look like across different groups, the data on average weight loss from Wegovy sets out the distribution in more detail. Understanding that range matters far more than fixating on the headline figure.

Wegovy works by activating GLP-1 receptors involved in appetite regulation and gastric emptying, reducing hunger and slowing how quickly food leaves the stomach. The biology is real; so is the variation in how people respond to it. A prescriber can help you think through where your own circumstances might put you.

How the 7.2mg dose changes the picture for average wegovy weight loss

Since January 2026, Wegovy's licensed maintenance dose in the UK has extended to 7.2mg weekly. The MHRA approved a dedicated single-dose 7.2mg pen on 14 April 2026 (one pre-set injection per week, built-in covered needle, locks after use) for adults with a BMI of 30 or above. Trials at this higher dose reported average weight loss of around 20.7% over 72 weeks, a result that approaches what tirzepatide 15mg achieves and substantially exceeds the 2.4mg figure.

That shift matters because many people who plateau on 2.4mg now have a clinically supervised route to a higher dose, provided their prescriber judges it appropriate. The titration schedule still starts at 0.25mg and steps up at roughly four-weekly intervals, the 7.2mg maintenance dose is not a starting point. How quickly Wegovy produces noticeable results depends partly on which part of the dose schedule someone is in; earlier weeks are adjustment weeks, not peak-effect weeks.

If you are curious about what average weight loss on Wegovy looks like across the full year, including the slower early months, the one-year results data gives a more granular picture of the trajectory.

What shapes your individual result on Wegovy

Clinical trials control for many variables that real life does not. In practice, average weight loss with Wegovy is influenced by several factors a trial average cannot capture for any one person.

Adherence to the full titration schedule matters considerably. Missing doses, reducing doses to manage side effects without clinical guidance, or stopping early all reduce the likelihood of reaching the average the trial produced. Gastrointestinal side effects (nausea, changes in bowel habit, occasional vomiting) are common in the early weeks and can lead people to stall at lower doses longer than the schedule intends; talking to a prescriber about managing them is more effective than quietly reducing the dose.

Diet and activity remain relevant even though Wegovy reduces appetite significantly. The trial participants received lifestyle support alongside the medicine. Protein intake in particular tends to matter when overall calorie intake falls, because preserving muscle mass keeps metabolic rate higher over the long term.

Starting weight is also a factor. People with a higher baseline BMI often see a larger absolute loss in kilograms, even when the percentage figure is similar. Those closer to the eligibility threshold may see smaller absolute numbers even with good adherence.

You can read more about the week-by-week Wegovy weight loss pattern or look at what the first month typically looks like, both give a more granular sense of the trajectory than the 68-week endpoint figure alone.

NHS criteria, private access and what to do next

NICE recommends semaglutide for weight management (under NICE technology appraisal TA875) for adults with a BMI of 35 or above and at least one weight-related comorbidity, used for a maximum of two years within a specialist weight management service. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. NHS waiting lists for specialist services are often long; many people who meet the licensed criteria (BMI of 30 or above, or 27 or above with a weight-related condition) access treatment privately through a regulated pharmacy while they wait or instead of waiting.

For context on what private treatment involves financially, the weight-loss treatments overview covers costs and what is typically included in a private prescription service. The honest position is that Wegovy is not a cheap medicine at any dose, and average wegovy weight loss figures are only meaningful if treatment is clinically supervised, genuine, and taken consistently.

If you are weighing up whether Wegovy is right for your situation, or comparing it with tirzepatide (Mounjaro), our clinical team at nume reviews every consultation personally. There is no algorithm making that call. If you would like an assessment, you are welcome to speak to our prescribers through a free consultation, no obligation, and the review happens the same day.